search
Back to results

Effect of a Low-Calorie Diet and/or Exercise Program on Risk Factors for Developing Breast Cancer in Overweight or Obese Postmenopausal Women

Primary Purpose

Breast Cancer, Obesity, Weight Changes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
behavioral dietary intervention
Exercise intervention
Sponsored by
Fred Hutchinson Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Breast Cancer focused on measuring breast cancer, obesity, weight changes

Eligibility Criteria

50 Years - 75 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

  • At increased risk for developing breast cancer due to any of the following lifestyle risk factors:

    • Lack of physical activity
    • Excess weight
    • Obesity
    • Weight gain over lifetime
  • Body mass index > 25.0
  • Physically able to undertake a moderate exercise or calorie reduction program
  • No history of invasive or in situ breast cancer

PATIENT CHARACTERISTICS:

  • Postmenopausal, defined by the absence of periods for the past 12 months
  • Able to attend study clinic visits and classes, and undergo study measurements
  • Able to fill out questionnaires and logs in English
  • No moderate to high alcohol intake (more than 2 drinks per day)
  • No concurrent smoking
  • No invasive cancer within the past 10 years except simple basal cell or squamous cell carcinoma
  • No diabetes mellitus

    • Fasting blood sugar < 126 mg/dL (on 2 occasions)
  • Hematocrit 32-48%
  • WBC 3,000-15,000/mm³
  • Potassium 3.5-5.0 mEq/L
  • Creatinine ≤ 2.0 mg/dL
  • No abnormalities on screening physical that contraindicate study participation
  • No contraindications for treadmill testing or entry into a training program, including any of the following:

    • Myocardial infarction within the past 6 months
    • Pulmonary edema
    • Myocarditis
    • Pericarditis
    • Unstable angina
    • Pulmonary embolism or deep vein thrombosis
    • Uncontrolled hypertension (i.e., blood pressure > 200/100 mm Hg)
    • Orthostatic hypotension
    • Moderate-to-severe aortic stenosis
    • Uncontrolled arrhythmia
    • Uncontrolled congestive heart failure
    • Third-degree heart block
    • Left bundle branch block
    • Thrombophlebitis
    • ST depression > 3 mm at rest
    • History of cardiac arrest or stroke
  • Normal exercise treadmill testing (ETT)

    • Negative thallium or echo ETT required for patients with abnormal ETT (defined as ≥ 1.5 mm ST depression in > 1 lead within 1-minute recovery OR ≥ 1.1 mm ST depression in > 1 lead after 1-minute recovery OR reading of positive test by study doctor)
  • No drug abuse
  • No significant mental illness

PRIOR CONCURRENT THERAPY:

  • More than 6 months since prior and no concurrent menopausal hormone replacement therapy of any type, including vaginal route
  • No concurrent participation in any other organized weight loss or exercise program
  • No concurrent appetite suppressant medication
  • No concurrent medications (e.g., weight-loss medications) likely to interfere with adherence to interventions or study outcomes

Sites / Locations

  • Fred Hutchinson Cancer Research Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Other

Other

Other

Arm Label

Control

Caloric Restriction

Exercise Intervention

Caloric Restriction AND Exercise Intervention

Arm Description

Nutritionist-delivered weight loss intervention though diet modification with an aim of 10% weightloss over a year long intervention based on the DPP and LookAHEAD interventions. Participants meet with a nutritionist individually and in small groups. Participants receive general information about diet and behavior strategies such as self-monitoring, goal-setting, stimulus-control, problem-solving, and relapse-prevention training. Participants learn to set a calorie goal and a fat gram goal and how to achieve the goal calorie reduction. Meetings are held weekly during the first 6 months of the diet program but taper off over the course of the study.

Participants exercise 3 days per week under the supervision of a physiologist and 2 days per week independently at home, for a total of 5 exercise sessions (at least 45 minutes of moderate-intensity exercise per session) weekly over 12 months

Combined caloric restriction & exercise intervention

Outcomes

Primary Outcome Measures

Serum estrone concentrations as measured by radioimmunoassay

Secondary Outcome Measures

Serum estradiol and free estradiol concentration as measured by radioimmunoassay
Testosterone and free testosterone as measured radioimmunoassay
Serum concentrations of Sex hormone binding globulin measured using immunoassays
Mammographic density measurements (i.e., percentage density and dense area of breast tissue)
Change in weight and body mass index (Anthropometrics)
Total and percentage body fat and body fat distribution (i.e., waist and hip circumferences) as measured by dual x-ray absorptiometry
Quality of life (assessed via questionnaires)
Change in daily caloric intake as measured by Food Frequency Questionnaire
Leukocyte and Neutrophil Counts
Serum concentrations of Insulin as measured radioimmunoassay
Serum concentrations of Glucose as measured radioimmunoassay
Serum concentrations of Insulin-like growth factor-1
Serum concentrations of Insulin-like growth-factor binding protein-3
Serum Vitamin D concentrations as measured by radioimmunoassay
Serum ghrelin concentrations as measured by radioimmunoassay
Serum C-reactive Protein (CRP) concentrations as measured by radioimmunoassay
Serum concentrations of Serum Amyloid A (SAA) as measured by radioimmunoassay
Serum interleukin-6 (IL-6) concentrations as measured by radioimmunoassay
Serum adiponectin concentrations as measured by radioimmunoassay
Serum leptin concentrations as measured by radioimmunoassay
Serum androtenedione concentrations as measured by radioimmunoassay
Serum c-peptide concentrations as measured by radioimmunoassay

Full Information

First Posted
May 3, 2007
Last Updated
September 7, 2012
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00470119
Brief Title
Effect of a Low-Calorie Diet and/or Exercise Program on Risk Factors for Developing Breast Cancer in Overweight or Obese Postmenopausal Women
Official Title
Exercise Diet and Sex Hormones in Postmenopausal Women (NEW)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
December 2004 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
February 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
RATIONALE: A low-calorie diet and/or exercise program may help lower an overweight or obese postmenopausal woman's risk of developing breast cancer. It is not yet known whether a low-calorie diet and/or exercise program are more effective than no diet or exercise program in lowering an overweight or obese postmenopausal woman's risk of developing breast cancer. PURPOSE: This randomized clinical trial is studying the effect of a low-calorie diet and/or exercise program on risk factors for developing breast cancer compared with no diet or exercise program in overweight or obese postmenopausal women.
Detailed Description
OBJECTIVES: Primary Compare the effects of a 1-year exercise intervention, reduced-calorie diet intervention, or a combined exercise and reduced-calorie diet intervention vs no intervention on serum estrone concentrations in overweight or obese postmenopausal women. Secondary Compare the effects of these interventions on serum levels of estradiol and free estradiol in these participants. Compare the effects of these interventions on serum levels of testosterone and free testosterone in these participants. Compare the effects of these interventions on serum levels of sex hormone binding globulin in these participants. Compare the effects of these interventions on serum levels of insulin in these participants. Compare the effects of these interventions on serum levels of glucose in these participants. Compare the effects of these interventions on serum levels of c-peptide in these participants. Compare the effects of these interventions on serum levels of insulin-like growth factor I (IGF-1) in these participants. Compare the effects of these interventions on serum levels of insulin-like growth factor binding-protein-3 (IGFBP-3) in these participants. Compare the effects of these interventions on serum levels of c-reactive protein (CRP) in these participants. Compare the effects of these interventions on serum levels of serum amyloid protein A (SAA) in these participants. Compare the effects of these interventions on serum levels of interleukin-6 (IL-6) in these participants. Compare the effects of these interventions on serum levels of adiponectin in these participants. Compare the effects of these interventions on serum levels of leptin in these participants. Compare the effects of these interventions on serum levels of ghrelin in these participants. Compare the effects of these interventions on serum levels of Vitamin D in these participants. Compare the effects of these interventions on mammographic density in these participants. Compare the effects of these interventions on anthropometrics and body composition (i.e., weight, body mass index, total and percentage body fat, and waist and hip circumferences) in these participants. Compare the effects of these interventions on quality of life in these participants. Compare the effects of these interventions on numbers of leukocytes and neutrophiles in these participants. Compare the effects of these interventions on VO2max in these participants. OUTLINE: This is a randomized study. Participants are stratified according to body mass index (< 30 vs ≥ 30). Participants are randomized to 1 of 4 intervention arms. Arm I (exercise program): Participants exercise 3 days per week under the supervision of a physiologist and 2 days per week independently at home, for a total of 5 exercise sessions (at least 45 minutes of moderate-intensity exercise per session) weekly over 12 months. Arm II (reduced-calorie diet): Participants meet with a nutritionist individually and in small groups. Participants receive general information about diet and behavior strategies such as self-monitoring, goal-setting, stimulus-control, problem-solving, and relapse-prevention training. Participants learn to set a calorie goal and a fat gram goal and how to achieve the goal calorie reduction. Meetings are held weekly during the first 6 months of the diet program but taper off over the course of the study. Arm III (exercise program and reduced-calorie diet): Participants meet with a physiologist and a nutritionist, as in arms I and II, and exercise and diet accordingly. Arm IV (control: delayed diet and exercise): Participants receive study materials on healthy diet and exercise at the end of the 12-month study period. In addition, participants are offered 2 months of group exercise training with a study physiologist and 4 group meetings with a nutritionist to learn about weight loss techniques and behavioral principles for achieving weight loss. All participants undergo testing at baseline and periodically during study. Participants undergo blood collection for evaluation of serum levels of sex and metabolic hormones (e.g., estrone, estradiol, testosterone, free testosterone, and sex hormone binding globulin, radioimmunoassay and other immunoassays. Participants also undergo anthropometrics and body composition measurements and mammographic density assessment. Participants complete questionnaires at baseline and at 6 and 12 months for assessment of diet and exercise. Quality of life (QOL) is measured at baseline and at 6 and 12 months using the Medical Outcomes Study 36-Item Short Form and the Impact of Weight on QOL questionnaire. Information on health habits, medical history, family history of breast cancer, and reproductive and menstrual history is also collected. FINAL ACCRUAL: A total of 439 participants (118 in the caloric restriction arm, and 117 in both the CR+Exercise, and exercise only arm; and 87 in control arm) were accrued for this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Obesity, Weight Changes
Keywords
breast cancer, obesity, weight changes

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
439 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Title
Caloric Restriction
Arm Type
Other
Arm Description
Nutritionist-delivered weight loss intervention though diet modification with an aim of 10% weightloss over a year long intervention based on the DPP and LookAHEAD interventions. Participants meet with a nutritionist individually and in small groups. Participants receive general information about diet and behavior strategies such as self-monitoring, goal-setting, stimulus-control, problem-solving, and relapse-prevention training. Participants learn to set a calorie goal and a fat gram goal and how to achieve the goal calorie reduction. Meetings are held weekly during the first 6 months of the diet program but taper off over the course of the study.
Arm Title
Exercise Intervention
Arm Type
Other
Arm Description
Participants exercise 3 days per week under the supervision of a physiologist and 2 days per week independently at home, for a total of 5 exercise sessions (at least 45 minutes of moderate-intensity exercise per session) weekly over 12 months
Arm Title
Caloric Restriction AND Exercise Intervention
Arm Type
Other
Arm Description
Combined caloric restriction & exercise intervention
Intervention Type
Behavioral
Intervention Name(s)
behavioral dietary intervention
Other Intervention Name(s)
Weight Loss interventions
Intervention Description
A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss
Intervention Type
Behavioral
Intervention Name(s)
Exercise intervention
Intervention Description
Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week
Primary Outcome Measure Information:
Title
Serum estrone concentrations as measured by radioimmunoassay
Time Frame
At baseline and 12 months timepoint
Secondary Outcome Measure Information:
Title
Serum estradiol and free estradiol concentration as measured by radioimmunoassay
Time Frame
At baseline and 12 months timepoint
Title
Testosterone and free testosterone as measured radioimmunoassay
Time Frame
At baseline and 12 months timepoint
Title
Serum concentrations of Sex hormone binding globulin measured using immunoassays
Time Frame
At baseline and 12 months timepoint
Title
Mammographic density measurements (i.e., percentage density and dense area of breast tissue)
Time Frame
At baseline and 12 months timepoint
Title
Change in weight and body mass index (Anthropometrics)
Time Frame
At baseline and 12 months timepoint
Title
Total and percentage body fat and body fat distribution (i.e., waist and hip circumferences) as measured by dual x-ray absorptiometry
Time Frame
At baseline and 12 months timepoint
Title
Quality of life (assessed via questionnaires)
Time Frame
At baseline and 12 months timepoint
Title
Change in daily caloric intake as measured by Food Frequency Questionnaire
Time Frame
At baseline and 12 months timepoint
Title
Leukocyte and Neutrophil Counts
Time Frame
Baseline and 12 month timepoints
Title
Serum concentrations of Insulin as measured radioimmunoassay
Time Frame
Baseline and 12 months
Title
Serum concentrations of Glucose as measured radioimmunoassay
Time Frame
Baseline and 12 month timepoints
Title
Serum concentrations of Insulin-like growth factor-1
Time Frame
Baseline and 12 month timepoints
Title
Serum concentrations of Insulin-like growth-factor binding protein-3
Time Frame
Baseline and 12-month timepoints
Title
Serum Vitamin D concentrations as measured by radioimmunoassay
Time Frame
Baseline and 12 month timepoints
Title
Serum ghrelin concentrations as measured by radioimmunoassay
Time Frame
Baseline and 12 month timepoints
Title
Serum C-reactive Protein (CRP) concentrations as measured by radioimmunoassay
Time Frame
Baseline and 12 month timepoints
Title
Serum concentrations of Serum Amyloid A (SAA) as measured by radioimmunoassay
Time Frame
Baseline and 12 month timepoints
Title
Serum interleukin-6 (IL-6) concentrations as measured by radioimmunoassay
Time Frame
Baseline and 12 month timepoints
Title
Serum adiponectin concentrations as measured by radioimmunoassay
Time Frame
Baseline and 12 month timepoints
Title
Serum leptin concentrations as measured by radioimmunoassay
Time Frame
Baseline and 12 month timepoints
Title
Serum androtenedione concentrations as measured by radioimmunoassay
Time Frame
Baseline and 12 month timepoints
Title
Serum c-peptide concentrations as measured by radioimmunoassay
Time Frame
Baseline and 12 month timepoints

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: At increased risk for developing breast cancer due to any of the following lifestyle risk factors: Lack of physical activity Excess weight Obesity Weight gain over lifetime Body mass index > 25.0 Physically able to undertake a moderate exercise or calorie reduction program No history of invasive or in situ breast cancer PATIENT CHARACTERISTICS: Postmenopausal, defined by the absence of periods for the past 12 months Able to attend study clinic visits and classes, and undergo study measurements Able to fill out questionnaires and logs in English No moderate to high alcohol intake (more than 2 drinks per day) No concurrent smoking No invasive cancer within the past 10 years except simple basal cell or squamous cell carcinoma No diabetes mellitus Fasting blood sugar < 126 mg/dL (on 2 occasions) Hematocrit 32-48% WBC 3,000-15,000/mm³ Potassium 3.5-5.0 mEq/L Creatinine ≤ 2.0 mg/dL No abnormalities on screening physical that contraindicate study participation No contraindications for treadmill testing or entry into a training program, including any of the following: Myocardial infarction within the past 6 months Pulmonary edema Myocarditis Pericarditis Unstable angina Pulmonary embolism or deep vein thrombosis Uncontrolled hypertension (i.e., blood pressure > 200/100 mm Hg) Orthostatic hypotension Moderate-to-severe aortic stenosis Uncontrolled arrhythmia Uncontrolled congestive heart failure Third-degree heart block Left bundle branch block Thrombophlebitis ST depression > 3 mm at rest History of cardiac arrest or stroke Normal exercise treadmill testing (ETT) Negative thallium or echo ETT required for patients with abnormal ETT (defined as ≥ 1.5 mm ST depression in > 1 lead within 1-minute recovery OR ≥ 1.1 mm ST depression in > 1 lead after 1-minute recovery OR reading of positive test by study doctor) No drug abuse No significant mental illness PRIOR CONCURRENT THERAPY: More than 6 months since prior and no concurrent menopausal hormone replacement therapy of any type, including vaginal route No concurrent participation in any other organized weight loss or exercise program No concurrent appetite suppressant medication No concurrent medications (e.g., weight-loss medications) likely to interfere with adherence to interventions or study outcomes
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne McTiernan, MD, PhD
Organizational Affiliation
Fred Hutchinson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fred Hutchinson Cancer Research Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109-1024
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
32859616
Citation
Duggan C, Tapsoba JD, Shivappa N, Harris HR, Hebert JR, Wang CY, McTiernan A. Changes in Dietary Inflammatory Index Patterns with Weight Loss in Women: A Randomized Controlled Trial. Cancer Prev Res (Phila). 2021 Jan;14(1):85-94. doi: 10.1158/1940-6207.CAPR-20-0181. Epub 2020 Aug 28.
Results Reference
derived
PubMed Identifier
31775800
Citation
Mason C, de Dieu Tapsoba J, Duggan C, Wang CY, Alfano CM, McTiernan A. Eating behaviors and weight loss outcomes in a 12-month randomized trial of diet and/or exercise intervention in postmenopausal women. Int J Behav Nutr Phys Act. 2019 Nov 27;16(1):113. doi: 10.1186/s12966-019-0887-1.
Results Reference
derived
PubMed Identifier
27417562
Citation
Duggan C, Tapsoba Jde D, Wang CY, McTiernan A. Dietary Weight Loss and Exercise Effects on Serum Biomarkers of Angiogenesis in Overweight Postmenopausal Women: A Randomized Controlled Trial. Cancer Res. 2016 Jul 15;76(14):4226-35. doi: 10.1158/0008-5472.CAN-16-0399.
Results Reference
derived
PubMed Identifier
25160845
Citation
Habermann N, Makar KW, Abbenhardt C, Xiao L, Wang CY, Utsugi HK, Alfano CM, Campbell KL, Duggan C, Foster-Schubert KE, Mason CE, Imayama I, Blackburn GL, Potter JD, McTiernan A, Ulrich CM. No effect of caloric restriction or exercise on radiation repair capacity. Med Sci Sports Exerc. 2015 May;47(5):896-904. doi: 10.1249/MSS.0000000000000480.
Results Reference
derived
PubMed Identifier
24930817
Citation
Duggan C, Xiao L, Terry MB, McTiernan A. No effect of weight loss on LINE-1 methylation levels in peripheral blood leukocytes from postmenopausal overweight women. Obesity (Silver Spring). 2014 Sep;22(9):2091-6. doi: 10.1002/oby.20806. Epub 2014 Jun 13.
Results Reference
derived
PubMed Identifier
23859929
Citation
Imayama I, Alfano CM, Mason C, Wang C, Duggan C, Campbell KL, Kong A, Foster-Schubert KE, Blackburn GL, Wang CY, McTiernan A. Weight and metabolic effects of dietary weight loss and exercise interventions in postmenopausal antidepressant medication users and non-users: a randomized controlled trial. Prev Med. 2013 Nov;57(5):525-32. doi: 10.1016/j.ypmed.2013.07.006. Epub 2013 Jul 13.
Results Reference
derived
PubMed Identifier
23190588
Citation
Mason C, Xiao L, Imayama I, Duggan CR, Foster-Schubert KE, Kong A, Campbell KL, Wang CY, Villasenor A, Neuhouser ML, Alfano CM, Blackburn GL, McTiernan A. Influence of diet, exercise, and serum vitamin d on sarcopenia in postmenopausal women. Med Sci Sports Exerc. 2013 Apr;45(4):607-14. doi: 10.1249/MSS.0b013e31827aa3fa.
Results Reference
derived
PubMed Identifier
22898251
Citation
Mason C, Foster-Schubert KE, Imayama I, Xiao L, Kong A, Campbell KL, Duggan CR, Wang CY, Alfano CM, Ulrich CM, Blackburn GL, McTiernan A. History of weight cycling does not impede future weight loss or metabolic improvements in postmenopausal women. Metabolism. 2013 Jan;62(1):127-36. doi: 10.1016/j.metabol.2012.06.012. Epub 2012 Aug 14.
Results Reference
derived
PubMed Identifier
21961463
Citation
Mason C, Foster-Schubert KE, Imayama I, Kong A, Xiao L, Bain C, Campbell KL, Wang CY, Duggan CR, Ulrich CM, Alfano CM, Blackburn GL, McTiernan A. Dietary weight loss and exercise effects on insulin resistance in postmenopausal women. Am J Prev Med. 2011 Oct;41(4):366-75. doi: 10.1016/j.amepre.2011.06.042.
Results Reference
derived
PubMed Identifier
21613554
Citation
Mason C, Xiao L, Imayama I, Duggan CR, Bain C, Foster-Schubert KE, Kong A, Campbell KL, Wang CY, Neuhouser ML, Li L, W Jeffery R, Robien K, Alfano CM, Blackburn GL, McTiernan A. Effects of weight loss on serum vitamin D in postmenopausal women. Am J Clin Nutr. 2011 Jul;94(1):95-103. doi: 10.3945/ajcn.111.015552. Epub 2011 May 25.
Results Reference
derived

Learn more about this trial

Effect of a Low-Calorie Diet and/or Exercise Program on Risk Factors for Developing Breast Cancer in Overweight or Obese Postmenopausal Women

We'll reach out to this number within 24 hrs